logo

For the Inventor, By the Inventor

Tokyo, Japan

Perseus Proteomics Inc.

Calculating rank
USPTO Granted Patents = 28

% Expired Patents = 50.0



Forward Citations = 63

Loading Chart...
Loading Chart...

73 inventors (with patents filed for the assignee):

goldMedal Hiroyuki Aburatani (12 out of 27 patents)

silverMedal Katsuyuki Mitomo (8 out of 9 patents)

bronzeMedal Hiroko Iwanari (8 out of 10 patents)

4.  Katsushi Kouda (7 out of 7 patents)

5.  Fumiko Nomura (6 out of 6 patents)

6.  Yukio Ito (6 out of 87 patents)

7.  Takao Hamakubo (6 out of 17 patents)

8.  Lilin Zhang (6 out of 6 patents)

9.  Keisuke Ishii (5 out of 28 patents)

10.  Yoko Kayukawa (5 out of 5 patents)

11.  Yoshitaka Hippo (5 out of 6 patents)

12.  Tatsuhiko Kodama (4 out of 31 patents)

13.  Hirotaka Ito (4 out of 25 patents)

14.  Gene Kurosawa (4 out of 7 patents)

15.  Tadashi Matsuura (4 out of 4 patents)


Core Competencies:
Cancer Diagnosis
Anti-CDH3 Antibody
Drug Conjugate
Therapeutic Agents
Gene Overexpression
Transferrin Receptor
PTX3 Measurement
Tumor Diagnostic Agent
ROBO1 Antibody
Alzheimer's Disease
Cell Membrane Surface Antigen
Monoclonal Antibody

28 patents:

1. 12767724 - METHOD OF TREATING CARCINOMATOUS PERITONITIS (2026-10-20),
2. 12752008 - Composition containing buffer (2026-10-06),
3. 11951168 - Composition containing buffer (2024-04-09),
4. 10030071 - Antibody which specifically reacts with human integrin A6B4 (2018-07-24),
5. 9764041 - Drug conjugate comprising anti-CDH3 (P-cadherin) antibody (2017-09-19),
6. 9644029 - Cancer diagnosis and treatment of cancer using anti-ROBO1 antibody (2017-05-09),
7. 9644028 - Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof (2017-05-09),
8. 9598496 - Antibody capable of specifically recognizing transferrin receptor (2017-03-21),
9. 9593165 - Antibody capable of specifically recognizing transferrin receptor (2017-03-14),
10. 9513292 - Method for diagnosing cancer by detecting GPC3 (2016-12-06),
11. 9434775 - Gene overexpressed in cancer (2016-09-06),
12. 9376475 - Gene overexpressed in cancer (2016-06-28),
13. 9328160 - Anti-CDH3 antibody having high internalization capacity (2016-05-03),
14. 9273140 - Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D (2016-03-01),
15. 9155805 - Monoclonal antibody, and use thereof (2015-10-13),
Company Overview
Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, specializing in advanced proteomics solutions. The organization focuses on the development of innovative technologies for protein analysis, enabling researchers to gain deeper insights into biological processes and disease mechanisms. By leveraging cutting-edge methodologies, Perseus Proteomics aims to enhance the understanding of protein functions and interactions, contributing to advancements in drug discovery and personalized medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

28 Patents

#1,114 in Tokyo

#2,417 in Japan

#23,317 in the World

Tokyo, JP
Tokyo, Japan

Perseus Proteomics Inc.

Forward Citations = 63

73 inventors:

goldMedal Hiroyuki Aburatani (12 out of 27 patents)

silverMedal Katsuyuki Mitomo (8 out of 9 patents)

bronzeMedal Hiroko Iwanari (8 out of 10 patents)

4.  Katsushi Kouda (7 out of 7 patents)

5.  Fumiko Nomura (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Perseus Proteomics Inc.. Retrieved from https://idiyas.com/company/perseus-proteomics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…